| Literature DB >> 33922125 |
Haoming Wu1,2,3, Yang Wang4, Huiying Li1,2,3, Lu Meng1,2,3, Nan Zheng1,2,3, Jiaqi Wang1,2,3.
Abstract
Endotoxin is a complex molecule derived from the outer membrane of Gram-negative bacteria, and it has strong thermal stability. The processing of infant food can kill pathogenic bacteria but cannot remove endotoxin. Because the intestinal structure of infants is not fully developed, residual endotoxin poses a threat to their health by damaging the intestinal flora and inducing intestinal inflammation, obesity, and sepsis, among others. This paper discusses the sources and contents of endotoxin in infant food and methods for preventing endotoxin from harming infants. However, there is no clear evidence that endotoxin levels in infant food cause significant immune symptoms or even diseases in infants. However, in order to improve the safety level of infant food and reduce the endotoxin content, this issue should not be ignored. The purpose of this review is to provide a theoretical basis for manufacturers and consumers to understand the possible harm of endotoxin content in infant formula milk powder and to explore how to reduce its level in infant formula milk powder. Generally, producers should focus on cleaning the milk source, securing the cold chain, avoiding long-distance transportation, and shortening the storage time of raw milk to reduce the level of bacteria and endotoxin. After production and processing, the endotoxin content should be measured as an important index to test the quality of infant formula milk powder so as to provide high-quality infant products for the healthy growth of newborns.Entities:
Keywords: alkaline phosphatase; endotoxin; infant formula; infant health
Year: 2021 PMID: 33922125 PMCID: PMC8143472 DOI: 10.3390/toxins13050298
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Endotoxin content in food.
| Model | Region | Sample Size/Dose | 100 mL/Day | References | |
|---|---|---|---|---|---|
| Raw milk | Raw and UHT milk 1 | Belgium | 0.19–5800 EU/mL | 19–580,000 EU | [ |
| Milk tanks | Hungary | 3–6144 EU/mL | 300–614,400 EU | [ | |
| Raw milk | Pullman, Wash | 10–1010 EU/mL | 1000–1012 EU | [ | |
| Raw milk | Germany | 1–107 EU/mL | 100–109 EU | [ | |
| Raw milk | Iran | 0.063–0.25 EU/mL | 6.3–25 EU | [ | |
| Low SCC 2 raw milk (health) | Japan | 0.27–2.16 EU/mL | 27–216 EU | [ | |
| High SCC raw milk (health) | 0.28–42.0 EU/mL | 28–4200 EU | |||
| Milk production | Processed shop milk | Hungary | 60–240 EU/mL | 600-24,000 EU | [ |
| Powdered instant formula milk | South Africa, | 40–55,000 EU/g | 400–550,000 EU | [ | |
| Other infant food products | Commercial infant cereal-based products | Sweden | 1400–24,200 EU/g | 14,000–242,000 EU | [ |
1 UHT milk, Ultra High Temperature treated milk, 2 SCC: somatic cell count.
Figure 1The intestinal barrier is not fully developed in infancy, and the thinner mucosa and intestinal structure make it easier for endotoxin to enter the blood. When endotoxin enters the circulation, it may stimulate inflammation in the liver, lung, and brain. However, for healthy adults, endotoxin can be removed by alkaline phosphatase reaction in intestinal mucosa to maintain health. Prebiotics and probiotics in food can help the intestinal tract resist the proliferation of microorganisms and the invasion of endotoxin.
Effects of endotoxin on health.
| Model | Strain/Dose | Administration | Exposure Time | Organ | Outcome | References |
|---|---|---|---|---|---|---|
| Infant rat | Oral gavage | 6 days | Intestinal | Slow physical development, inflammation of intestinal tissue, increased TNF-α in plasma and lung, and increased CINC-1 in plasma, liver, lung, and distal small intestine | [ | |
| Mice | LPS (O111:B4) | Oral gavage | 2 h | Intestinal | LPS increased anxiety-like and decreased repetitive behaviors in wild type (WT) mice of both sexes. | [ |
| Infant rats | Oral gavage | 6 days | Intestinal | Intestinal malformation; CINC mRNA secretion increased | [ | |
| Broiler Chickens | Oral gavage | 10 h | Intestinal | IL-6, IL-1β, and HSP70 increased; | [ | |
| Mice | LPS (O111:B4) | Oral gavage | Twice a week | Intestinal | Abrogated the protection offered by gut microbiota eradication | [ |
| Mice | Oral gavage | 23 h | Chorda tympani nerve (CT) | Sensitivity to sweetness and saltiness was reduced | [ | |
| Rat | Injected | 5 days | Intestinal | The presence of intestinal oxidative stress and increased intestinal permeability | [ | |
| Mice | LPS (not described) | Posterior pharyngeal instillation | 1 h | Lung | Alveolar epithelial cell injury and increased vascular permeability; vascular endothelial growth factor receptor (VEGF/VEGFR) and TLR4/NF-κB pathways are involved in the development of LPS-stimulated ALI. | [ |
| Human | Injected | 4 h | Intestinal | Secretion of TNF-α and IL-6 and anorexia response | [ | |
| Mice | EtoH + LPS | Injected | 6 h | Liver | Liver injury | [ |
| Human | Injected | 0, 3, 6, 12, and 24 h | Blood | Glucagon-like peptide 1 (GLP-1) and Toll-like receptor 4 (TLR4) increased | [ | |
| Mice | Injected | 5 days | Intestinal | Memory impairment and colitis, and increased the absorption of orally administered LPS into the blood | [ | |
| Rat | LPS | Injected | 4 h | Blood | MIP-1 α, IL-10, MCP-1, IP-10, fractalkine, and TNF-α were increased, but there was no sign of fever | [ |
| Rat | Oral gavage | 24 h | Intestinal | Inflammatory factor expression and intestinal epithelial damage | [ |
Substances that inhibit endotoxin toxicity.
| Model | Strain/Dose | Therapeutic Dose | Outcome | References | |
|---|---|---|---|---|---|
| Nutrients | Mice | Metabolic syndrome | Intestinal AP | Inhibited the absorption of endotoxin (LPS) induced by dietary fat | [ |
| Infant | Infant cardiopulmonary bypass (CPB) | Human liver AP | Reduced the harmful effects of endotoxemia following infant CPB | [ | |
| Rats | Lactoferrin | Serum levels of TNF-α and IL-6 were significantly decreased | [ | ||
| Infant rat | Intestinal inflammation | Glutamine (Gln) | Endotoxin-induced intestinal inflammatory response was reduced | [ | |
| Probiotics | Rats | LPS |
| Increased IGF-1 expression and enhanced intestinal immune barrier function in endotoxin injured rats | [ |
| Mice | LPS isolated from | Reduced the levels of intestinal microflora and LPS in blood and alleviated memory impairment and colitis caused by TNBS and EC | [ | ||
| Drugs/treatments | Mice | LPS (not described) | 20 mg/kg SU5416 + BW solution in DMSO | Inhibition of VEGF/VEGFR and TLR4/NF-κB signaling | [ |
| Mice | LPS (not described) | Resolvin E1; | Synthesis of alkaline phosphatase (ALP) to relieve endotoxin toxicity | [ | |
| Rats | LPS (20 mg/kg) | Ketamine | LPS-induced gastric effusion and iNOS expression in the stomach and ileum were decreased | [ | |
| SD rat | Salidroside (Sal) | Inhibition of iNOS, COX-2, NF-κB, and PI 3K/Akt/mTOR pathway/protection of heart from endotoxin | [ | ||
| Human | Endotoxin shock | endotoxin adsorption method (PMX-DHP) | Decreased procalcitonin (PCT) and endotoxin in blood | [ |